nd ESTRO Forum 2013 S129 marker motion during an arc with irregular breathing. Intrafraction motion caused a mean 3D target position error of 3.3 mm, resulting in a mean D 95 reduction of 6.6% over all fractions. The D 95 reduction correlated with the mean 3D target position error during a fraction (p < 0.001, Fig. B) . Conclusions: Kilovoltage imaging for detailed motion monitoring and dose reconstruction during VMAT liver SBRT was demonstrated for the first time. Large dosimetric impact of intrafraction tumor motion was observed. Although all patients received the prescribed dose (since dose is prescribed to the 67% level) the results show that intrafraction motion adaptation is warranted to maximize the CTV dose, especially for SBRT treatments where the convention has been to prescribe a peaked non-uniform PTV dose that gradually decreases outside the CTV.
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Erasmus Medical Center Rotterdam, Radiation Oncology, Rotterdam, The Netherlands
Purpose/Objective: Markers are often used to track lung tumors. However markers placed outside the tumor may not move synchronously to the tumor during breathing thereby potentially introducing errors in tumor tracking. The purpose of this study is to identify factors which influence non-synchronous marker motion, and to evaluate methods to exclude markers for tumor tracking in order to minimize the tracking error. Materials and Methods: Data of 53 patients with 64 tumors were studied. Marker and tumor motion was assessed using a 4DCT scan. Inhouse developed software was used to automatically register the tumor in the end-expiration phase to the tumor in the end-inspiration phase. Non-synchronous marker motion was defined by the vector connecting a marker on the end-expiration phase CT-scan to the corresponding marker on the registered end-inspiration phase CTscan. The tracking error was defined as the difference in the center of mass of the included markers on the end-expiration CT-scan and the registered end-inspiration CT-scan. Multivariate linear regression analysis was performed to evaluate the association between nonsynchronous marker motion and 1) the amplitude of tumor motion, 2) the distance between the marker and the tumor edge, 3) the location of the marker relative to the tumor (same lobe or different lobe) 4) the type of marker (coil or percutaneously-placed marker) and 5) the location of the tumor (against the chest wall or not). We examined if the tracking error could be reduced by excluding markers for tumor tracking based on 1) the distance of the marker to the tumor edge and 2) the extent of non-synchronous marker motion during breathing as determined on the 4DCT scan. The value of the two exclusion parameters was varied such that for all patients at least 1 marker was available for tracking. Results: Non-synchronous marker motion during the breathing cycle was 0.2±1.4 mm (mean±1SD) in LR direction, 0.4±1.6 mm in AP direction, and -0.3±2.9 mm in CC direction. Factors which significantly increased non-synchronous motion were increasing amplitude of tumor motion (p<0.01), increasing distance between the marker and the tumor edge (p<0.01), and the location of the tumor against the chest wall (p<0.01). The tracking error due to non-synchronous tumor marker motion could be reduced by excluding markers based on the distance of the marker to the tumor edge (fig 1a) . More effective was excluding markers based on their non-synchronous motion during breathing as assessed by 4DCT. By excluding markers with nonsynchronous motion ≥3.5 mm, the standard deviation of the tracking error was reduced from 1.4 to 0.8 mm (LR), 1.2 to 1.0 mm (AP), 2.0 to 0.9 mm (CC) (fig 1b) .
Conclusions:
Precise tumor tracking requires a 4DCT scan to identify and exclude markers with non-synchronous motion. This allows a reduction in the standard deviation of the tracking error by as much as 50%. Exclusion of markers based on the distance to the tumor edge was less effective. 
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German Cancer Research Center (DKFZ), Academic Physics, Heidelberg, Germany
Purpose/Objective: 4D CBCT images acquired on linac-based scanners are usually reconstructed by extracting the motion information from the 2D projections (or an external surrogate signal), and binning the individual projections into one or multiple breathing phases. In this 'after-the-fact' binning approach, however, imaging dose might be administered in breathing phases not desired for reconstruction. For 4D reconstructions, the image quality can be compromised by an uneven distribution of projections over respiratory phases and angles. We have therefore developed control software which actively triggers 2D projections based on the predicted position of the tumour. The prediction is derived from internal tumour positions reported by the Calypso electromagnetic (EM) tracking system. Materials and Methods: Due to the radio emissions of the EM-array, it is impossible to simultaneously operate EM tracking and acquire artefact-free images without shielding the detector. For this study we have used a very thin aluminium Faraday 'cage' for the detector that removes most EM-induced artefacts. We have also implemented new control software which receives a continuous stream (10 Hz) of 3D tumour positions from the EM-device. The position information of a sliding training window is used to predict a new position (120 ms in the future) using a support vector machine. The predicted position is then classified as e.g. peak-inhale according to the amplitude of the last respiratory cycle. Depending on the desired breathing phase and maximum angular spacing between images, a new 2D projection is triggered. We have used a lung phantom moving on a sin 4 trajectory with 15 mm amplitude and a 3.5 sec period for our study. A tumour model made from RW3 and the EM transponders were implanted into the phantom. For kV images which were superimposed by the projection of the EM-array (i.e. its internal antenna), image processing was used to replace pixels depicting the antenna by neighbouring 'good' pixels. 3D images were then reconstructed using an FDK algorithm provided by Siemens. nd ESTRO Forum 2013
Results:
We were able to demonstrate the feasibility of our new acquisition technique for peak-inhale only, peak-exhale only, and midventilation only short (200°) and full scanning protocols. In the figure, a significant reduction in motion-related artefacts at the tumour surface is demonstrated. Reconstruction artefacts stemming from the presence of the EM-array were greatly reduced. Inherently, the method leads to a smooth distribution of projection angles over the entire gantry rotation. A typical CTDI imaging dose for a peak-exhale (360°, 375 fr., 5 min)/peak-inhale (200°, 106 fr., 2:47 min) protocol is ~8/~2 mGy.
Conclusions:
We have implemented a new dose-saving 4D CBCT scanning protocol which reduces motion-artefacts by selecting the breathing phase(s) desired for reconstruction prior to image acquisition. We are currently implementing the acquisition of multiple phases in one gantry rotation. Purpose/Objective: To develop and evaluate a tumour tracking method for the dynamic localization of extra-cranial targets during radiotherapy treatments, providing the continuous monitoring and compensation of intra-fraction organ motion due to breathing. The proposed approach is based on external surface surrogates estimated from non-invasive optical devices, and on patient-specific adaptive motion models derived from time-resolved planning and in-room X-ray imaging systems. Materials and Methods: A patient-specific motion model, parameterized as a function of the respiratory tumour baseline, amplitude and phase, is estimated from 4D CT planning images, by applying B-spline deformable registration between each 4D CT phase and the mid-position CT volume.The tumour baseline is adapted at each treatment fraction according to daily information on target localization derived from volumetric CBCT images. The breathing amplitude and phase parameters are retrieved from the external surface motion, acquired with 3D surface imaging systems. Deformable mesh registration is applied to derive the spatial correspondence between markerless optical surfaces. The obtained 3D trajectories of all thoraco-abdominal surface points are summarized into a single respiratory surrogate signal through k-means clustering techniques. The instantaneous values of the respiratory phase are extracted from the surface surrogate using the Hilbert transform. The amplitude scaling factor is obtained by comparing surface motion amplitudes during treatment planning and delivery. The adapted breathing parameters are integrated in the 4D CT motion model to estimate intra-fraction 3D tumor motion. Results: The developed tumour tracking method was tested on a clinical database of seven lung cancer patients, including the synchronized information on the external surface and internal tumour breathing motion during CBCT scans. About 30 seconds of synchronized acquisition of CBCT projections and optical surfaces, captured with the VisionRT system, were analyzed for each patient. The tumour trajectories estimated from surface displacement combined with the a priori 4D CT motion model were compared to the real target trajectories identified on CBCT images. The resulting absolute differences between real and estimated tumour motion ranged between 0.7 and 2.4 mm, with median values of 1.5 mm both along the horizontal and vertical image dimensions (Table 1 ). The measured phase shifts did not exceed the 7% of the breathing cycle length.
OC-0335 Tumour motion tracking technique based on dynamic surface scanning and 4D CT breathing motion model
Conclusions:
The developed tumor tracking method proved to be effective in estimating tumour motion from the external surface displacement even in presence of breathing irregularities, as depicted in Figure 1 . The innovative methodological aspects, related to the use of patient-specific adaptive motion models and to the redundancy of markerless surface data, are put forward to improve the accuracy and robustness of targeting techniques for intra-fraction organ motion compensation.
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Inter-and intrafractional relative motion of implanted fiducial markers in the liver W. Purpose/Objective: In radiotherapy, fiducial markers are often implanted in the liver and used as x-ray visible surrogates for the tumour position. The basic assumption is that the tumour maintains a constant position relative to the marker throughout the treatment course. The aim of this study was to investigate the validity of this assumption by quantifying the geometric accuracy by which one implanted marker can predict the position of another marker in the liver. Materials and Methods: 26 patients with 2-3 implanted gold markers received stereotactic body radiation therapy to liver lesions in 3-6 treatment fractions. At each fraction a cone-beam CT (CBCT) scan was acquired and used for marker based patient setup. After the treatments each marker was segmented in the projections of the CBCT scans, and the resulting 2D marker trajectories were used to estimate the 3D trajectory of each marker in patientspace by a probability based method. In total 198 3D marker trajectories with a mean duration of 51 seconds were recorded at 11 Hz over 90 treatment fractions. The markers in the data set constituted 54 marker pairs in total. For each marker pair, the error in estimating the 3D position of one marker from the 3D position of the other marker was calculated for each time point as the difference in the 3D shifts the two markers away from their respective mean positions. The root-mean-square (RMS) of this error was calculated for each marker pair as a measure for the intrafraction prediction error, during all fractions. Similarly, the interfraction RMS estimation error was calculated for each marker pair from the changes in the relative 3D mean marker positions from fraction to fraction. Results: The 3D position of an implanted marker was estimated from the position of another marker with a mean RMS error of 0.35 (LR), 0.59 mm (CC), 0.47 mm (AP), and 0.86 +-0.57 mm (3D) intrafractionally, and of 0.52 mm (LR), 0.60 mm (CC), 0.59 mm (AP), and
